©2022 Stanford Medicine
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
Not Recruiting
Trial ID: NCT05219981
Purpose
In this study, patients with advanced solid tumors will undergo [18F]F AraG PET/CT imaging to
assess for changes in tracer uptake following treatment with CkIT.
Official Title
A Pilot Study of Using [18F]F AraG PET Imaging to Evaluate the Immunological Response to Checkpoint Inhibitor Therapy (CkIT) in Patients With Advanced Solid Tumors
Stanford Investigator(s)
David S. Wang, MD
Clinical Associate Professor, Radiology
Nam Quoc Bui
Clinical Assistant Professor, Medicine - Oncology
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:
- Solid tumor with planned CkIT
- Must be >18 years old
- Signed Informed Consent Form
- Patient must have two qualifying lesions
Exclusion Criteria:
- Patient is pregnant or breast feeding
Intervention(s):
drug: [18F]F-AraG
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Isabel Galvez Leonio
650-723-0371